FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896795635> ?p ?o ?g. }

• W2896795635 abstract "It has been recognized that circulating tumor cells (CTCs) shed by a primary tumor can be a valuable surrogate to tissue biopsies. Our project goal is to develop a CTC-based liquid biopsy platform as a noninvasive method for identifying primary and secondary mutations in non-small lung cancer to direct personalized therapies. The high-throughput, label-free and size-based inertial microfluidic separation device “Labyrinth” developed in the Nagrath lab has been used for simultaneous isolation of epithelial (EpCs) and mesenchymal (EMTCs) CTCs from lung cancer patients. The total channel length of Labyrinth is 637 mm, with 500 mm in width and 100 mm in height. The device consists of complex of small and high ratio of curvature structures (11 long loops and sharp right-angle 56 corners) to enhance differential focusing of both CTCs and white blood cells into separate fluid streams in the outlet area. The high recoveries and advantage of size-based biomarker independent separation are crucial for the downstream applications including molecular characterization of CTCs (mutation and mRNA profiling) and expansion of CTCs in vitro. Labyrinth was optimized and tested for inertial separation of cancer cells using the human lung cancer cell line PC-9. The percentage of recovery and purity was >93% with 2400 µL/min flow rate. We have enrolled 15 metastatic patients for this study and isolated CTCs from baseline (n=15) and post-therapy follow-up visits (range 1-4). To be able to detect different subpopulations of CTCs including EpCs and EMTCs from patients, we have employed immunofluorescence to label EpCAM (for EpCs) and Vim (for EMTCs), in addition to PanCK (tumor marker) and CD45 (leukocyte marker). CTCs were defined as EpCAM+/-/ Vim+/-/ PanCK+/ CD45-. All 15 patients, with different mutations/fusion, including EGFR, RET, ROS1, and ALK, had detectable CTCs at all visits, including 156±175 (at baseline, n=15), 141±133 (at visit 1, n=14), 255±218 (at visit 2, n=8), 84±81 (at visit 3, n=4), and 157±177 per mL (at visit 4, n=2). Patients with EGFR mutants had an average of 112±97 total CTCs per mL at their baseline and 66±57 after they were treated with either erlotinib or osimertanib. Patients with ROS1 fusion had slightly higher total CTCs per mL at their baseline (185±250) and during treatment with crizotinib (120±113) compared to EGFR mutant patients. To expand patient-derived CTCs for ex vivo drug testing, three different CTC culture conditions were tested: a plain, a “Fibronectin coated” (2D), and a “Matrigel-collagen-irradiated mice fibroblast coated” (3D) 48-well plate. After 6 weeks in culture, the growth rate was significantly higher in the 3D model. For CTC expansion, the enrichment methods require further optimization prior to adopting the 3D culture model for future samples. The cell surface marker independent microfluidic device, Labyrinth, isolated heterogeneous CTC subpopulations that were characterized and expanded in vitro. This could allow ex vivo drug testing to direct patient-specific therapies. Citation Format: Mina Zeinali, Arthi Nadhan, Anvya Mathur, Maggie Lee, Wei Huang, Mathias Hafner, Nithya Ramnath, Sunitha Nagrath. High-throughput isolation of circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients for personalized treatments [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr A21." @default.
• W2896795635 created "2018-10-26" @default.
• W2896795635 creator A5006462611 @default.
• W2896795635 creator A5008169438 @default.
• W2896795635 creator A5013480378 @default.
• W2896795635 creator A5020899618 @default.
• W2896795635 creator A5029455151 @default.
• W2896795635 creator A5048171248 @default.
• W2896795635 creator A5058716360 @default.
• W2896795635 creator A5087704838 @default.
• W2896795635 date "2018-09-01" @default.
• W2896795635 modified "2023-10-14" @default.
• W2896795635 title "Abstract A21: High-throughput isolation of circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients for personalized treatments" @default.
• W2896795635 doi "https://doi.org/10.1158/1557-3265.aacriaslc18-a21" @default.
• W2896795635 hasPublicationYear "2018" @default.
• W2896795635 type Work @default.
• W2896795635 sameAs 2896795635 @default.
• W2896795635 citedByCount "0" @default.
• W2896795635 crossrefType "proceedings-article" @default.
• W2896795635 hasAuthorship W2896795635A5006462611 @default.
• W2896795635 hasAuthorship W2896795635A5008169438 @default.
• W2896795635 hasAuthorship W2896795635A5013480378 @default.
• W2896795635 hasAuthorship W2896795635A5020899618 @default.
• W2896795635 hasAuthorship W2896795635A5029455151 @default.
• W2896795635 hasAuthorship W2896795635A5048171248 @default.
• W2896795635 hasAuthorship W2896795635A5058716360 @default.
• W2896795635 hasAuthorship W2896795635A5087704838 @default.
• W2896795635 hasConcept C121608353 @default.
• W2896795635 hasConcept C126322002 @default.
• W2896795635 hasConcept C142724271 @default.
• W2896795635 hasConcept C143998085 @default.
• W2896795635 hasConcept C2776256026 @default.
• W2896795635 hasConcept C2779013556 @default.
• W2896795635 hasConcept C2779529041 @default.
• W2896795635 hasConcept C502942594 @default.
• W2896795635 hasConcept C61238886 @default.
• W2896795635 hasConcept C71924100 @default.
• W2896795635 hasConceptScore W2896795635C121608353 @default.
• W2896795635 hasConceptScore W2896795635C126322002 @default.
• W2896795635 hasConceptScore W2896795635C142724271 @default.
• W2896795635 hasConceptScore W2896795635C143998085 @default.
• W2896795635 hasConceptScore W2896795635C2776256026 @default.
• W2896795635 hasConceptScore W2896795635C2779013556 @default.
• W2896795635 hasConceptScore W2896795635C2779529041 @default.
• W2896795635 hasConceptScore W2896795635C502942594 @default.
• W2896795635 hasConceptScore W2896795635C61238886 @default.
• W2896795635 hasConceptScore W2896795635C71924100 @default.
• W2896795635 hasLocation W28967956351 @default.
• W2896795635 hasOpenAccess W2896795635 @default.
• W2896795635 hasPrimaryLocation W28967956351 @default.
• W2896795635 hasRelatedWork W1572187624 @default.
• W2896795635 hasRelatedWork W2063261090 @default.
• W2896795635 hasRelatedWork W2156708214 @default.
• W2896795635 hasRelatedWork W2203524221 @default.
• W2896795635 hasRelatedWork W2791812312 @default.
• W2896795635 hasRelatedWork W2963417556 @default.
• W2896795635 hasRelatedWork W2978674196 @default.
• W2896795635 hasRelatedWork W3029946322 @default.
• W2896795635 hasRelatedWork W3209475169 @default.
• W2896795635 hasRelatedWork W3209878224 @default.
• W2896795635 isParatext "false" @default.
• W2896795635 isRetracted "false" @default.
• W2896795635 magId "2896795635" @default.
• W2896795635 workType "article" @default.